Cargando…

Alzheimer’s disease CSF biomarkers: clinical indications and rational use

This review focusses on the validation and standardization of Alzheimer’s disease (AD) cerebrospinal fluid (CSF) biomarkers, as well as on the current clinical indications and rational use of CSF biomarkers in daily clinical practice. The validated AD CSF biomarkers, Aβ(1-42), T-tau, and P-tau(181),...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niemantsverdriet, Ellis, Valckx, Sara, Bjerke, Maria, Engelborghs, Sebastiaan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565643/ https://www.ncbi.nlm.nih.gov/pubmed/28752420 http://dx.doi.org/10.1007/s13760-017-0816-5

Ejemplares similares

Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer’s Disease Diagnosis
por: Bjerke, Maria, et al.
Publicado: (2018)

Biomarker A+T−: is this Alzheimer’s disease or not? A combined CSF and pathology study
por: Vromen, Eleonora M, et al.
Publicado: (2022)

Callosal circularity as an early marker for Alzheimer's disease
por: Van Schependom, Jeroen, et al.
Publicado: (2018)

Cerebrospinal fluid inflammatory biomarkers for disease progression in Alzheimer’s disease and multiple sclerosis: a systematic review
por: Temmerman, Joke, et al.
Publicado: (2023)

Investigating Tissue-Specific Abnormalities in Alzheimer’s Disease with Multi-Shell Diffusion MRI
por: Giraldo, Diana L., et al.
Publicado: (2022)

Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios
por: Bouwman, Femke H., et al.
Publicado: (2022)

Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer’s Disease
por: Niemantsverdriet, Ellis, et al.
Publicado: (2016)

A simulation study on the impact of the blood flow-dependent component in [(18)F]AV45 SUVR in Alzheimer’s disease
por: Ottoy, Julie, et al.
Publicado: (2017)

Added Diagnostic Value of Cerebrospinal Fluid Biomarkers for Differential Dementia Diagnosis in an Autopsy-Confirmed Cohort
por: Niemantsverdriet, Ellis, et al.
Publicado: (2018)

No added diagnostic value of non-phosphorylated tau fraction (p-tau(rel)) in CSF as a biomarker for differential dementia diagnosis
por: Goossens, Joery, et al.
Publicado: (2017)

Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and (18)F-FDG-PET imaging
por: Ottoy, Julie, et al.
Publicado: (2019)

CSF biomarker analysis of ABCA7 mutation carriers suggests altered APP processing and reduced inflammatory response
por: Duchateau, Lena, et al.
Publicado: (2023)

A Retrospective Belgian Multi-Center MRI Biomarker Study in Alzheimer’s Disease (REMEMBER)
por: Niemantsverdriet, Ellis, et al.
Publicado: (2018)

Genome-wide association study of Alzheimer’s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset
por: Hong, Shengjun, et al.
Publicado: (2020)

Cerebrospinal Fluid P-Tau(181P): Biomarker for Improved Differential Dementia Diagnosis
por: Struyfs, Hanne, et al.
Publicado: (2015)

Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia
por: Chiasserini, Davide, et al.
Publicado: (2017)

CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease
por: del Campo, Marta, et al.
Publicado: (2023)

CSF Biomarkers for Alzheimer's Disease Diagnosis
por: Anoop, A., et al.
Publicado: (2010)

Higher susceptibility to 6 Hz corneal kindling and lower responsiveness to antiseizure drugs in mouse models of Alzheimer's disease
por: Vande Vyver, Maxime, et al.
Publicado: (2022)

Automated MRI volumetry as a diagnostic tool for Alzheimer's disease: Validation of icobrain dm
por: Struyfs, Hanne, et al.
Publicado: (2020)

Variability of CSF Alzheimer’s Disease Biomarkers: Implications for Clinical Practice
por: Vos, Stephanie J. B., et al.
Publicado: (2014)

The Cerebrospinal Fluid Aβ(1–42)/Aβ(1–40) Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer’s Disease in a Clinical Setting
por: Niemantsverdriet, Ellis, et al.
Publicado: (2017)

Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team
por: Arnerić, Stephen P., et al.
Publicado: (2016)

Melatonin levels in the Alzheimer’s disease continuum: a systematic review
por: Nous, Amber, et al.
Publicado: (2021)

The Use of Biomarkers and Genetic Screening to Diagnose Frontotemporal Dementia: Evidence and Clinical Implications
por: Gossye, Helena, et al.
Publicado: (2019)

Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease
por: Buchhave, Peder, et al.
Publicado: (2009)

Current Biomarkers for Alzheimer’s Disease: From CSF to Blood
por: Zou, Kun, et al.
Publicado: (2020)

CSF metabolites associated with biomarkers of Alzheimer’s disease pathology
por: Dong, Ruocheng, et al.
Publicado: (2023)

CSF P-tau 231 as Biomarker in Alzheimer's Disease
por: Mukherjee, Adreesh, et al.
Publicado: (2022)

Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer’s Disease
por: Geijselaers, Stefan L.C., et al.
Publicado: (2017)

Alzheimer’s Disease CSF Biomarkers as Possible Indicators of Tap-Test Response in Idiopathic Normal Pressure Hydrocephalus
por: Pyrgelis, Efstratios-Stylianos, et al.
Publicado: (2023)

Comparison of Two Analytical Platforms for CSF Biomarkers of Alzheimer's Disease
por: Monge-Argilés, Jose Antonio, et al.
Publicado: (2014)

White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation
por: Teunissen, Charlotte E., et al.
Publicado: (2018)

Development of Alzheimer’s Disease Biomarkers: From CSF- to Blood-Based Biomarkers
por: Mankhong, Sakulrat, et al.
Publicado: (2022)

Methodological Issues in the Clinical Validation of Biomarkers for Alzheimer’s Disease: The Paradigmatic Example of CSF
por: Canevelli, Marco, et al.
Publicado: (2019)

Recognizing Atypical Presentations of Alzheimer’s Disease: The Importance of CSF Biomarkers in Clinical Practice
por: Paraskevas, George P., et al.
Publicado: (2022)

Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning
por: Neumann, Alexander, et al.
Publicado: (2023)

CSF Biomarkers in the Early Diagnosis of Mild Cognitive Impairment and Alzheimer’s Disease
por: Papaliagkas, Vasileios, et al.
Publicado: (2023)

Relation between Alpha-Synuclein and Core CSF Biomarkers of Alzheimer’s Disease
por: Monge-García, Victoria, et al.
Publicado: (2021)

CSF Proteomic Alzheimer’s Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals
por: Tijms, Betty Marije, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_401417097r2ujkm5sj6475p0mf